Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. develops AI-driven precision oncology therapies and research platforms for cancer drug discovery. The company uses its proprietary RADR® platform to identify and advance small-molecule oncology candidates, including LP-300, LP-184 and LP-284, and develops STAR-001 for CNS cancers through Starlight Therapeutics, its wholly owned subsidiary.
Recurring news includes clinical-program updates for lung cancer, hematologic cancers, sarcomas and brain cancers; FDA and trial-design communications; financial results; and commercialization of AI tools such as withZeta.ai and predictBBB.ai. Company updates also cover subscription-based platform access, computational biology features and enterprise deployment for biomedical research and drug-development users.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced it will hold a conference call on November 1, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial and operating results. This conference aims to provide insights into the company's performance and upcoming milestones. Led by CEO Panna Sharma, the management team will also highlight the use of its RADR® A.I. platform for oncology drug discovery. Interested parties can register for the event via the company's website.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced its invitation to present at the Fall Harvest - Best Ideas from the Buy-Side conference, scheduled for October 5-8, 2021. CEO Panna Sharma will present on October 6 at 10:00 AM ET. The live webcast will be available for replay after the event. Lantern Pharma leverages its RADR A.I. platform to enhance oncology drug discovery, currently developing four drug candidates across eight tumor targets. Investors can register for the conference and schedule one-on-one meetings.
Lantern Pharma (LTRN) announced a strategic collaboration with Deep Lens, aimed at accelerating patient enrollment for its Phase 2 clinical trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC). This partnership integrates Deep Lens' VIPER AI platform, enhancing patient matching to clinical trials. Lantern's RADR® AI technology will help identify biomarker signatures for effective oncological therapies. The goal is to streamline the complex drug development process, reduce costs, and improve access to treatments for cancer patients, particularly in the underserved demographic of never-smokers.
Lantern Pharma (NASDAQ: LTRN) announced that President & CEO Panna Sharma will present at the Benzinga Healthcare Small Cap Conference virtually from September 29-30, 2021. Sharma's presentation is scheduled for September 29 at 11:55 AM ET, with one-on-one meetings available throughout the event. Lantern Pharma is focused on oncology drug development, utilizing its proprietary RADR® A.I. platform to identify patients likely to benefit from their genomically targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.
Lantern Pharma (NASDAQ: LTRN) announced key additions to its leadership team to strengthen its clinical and manufacturing operations. Dr. Harry Kochat takes on the role of Senior Director of Chemistry, Manufacturing and Controls, bringing over 30 years of experience in drug development and quality control. Darlene Bunpian joins as Clinical Trial Project Manager, overseeing the planned Phase 2 trial of LP-300 in Non-Small Cell Lung Cancer. The company aims to advance its oncology drug development utilizing its RADR® A.I. platform, while the new appointments are expected to enhance operational capabilities.
Lantern Pharma (LTRN) announced positive preclinical results for its drug candidate LP-184 against glioblastoma (GBM). The study showed LP-184 inhibits tumor growth by over 106% and extends survival in mice by 27% compared to controls. Conducted with Johns Hopkins, the findings support LP-184's potential in treating GBM, particularly in patients unresponsive to standard therapies. Lantern plans to refine dosing regimens and strengthen its FDA orphan drug application. This signifies a step towards addressing critical gaps in GBM treatment, benefiting patients with varying tumor profiles.
Lantern Pharma (LTRN) announced that its abstract, titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects', has been accepted for presentation at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, 2021. The abstract highlights LP-184's promising efficacy in pancreatic cancer models, especially with DNA repair deficiencies. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment.
Lantern Pharma (LTRN) announced that the FDA has granted Orphan Drug Designation for its drug candidate LP-184, aimed at treating pancreatic cancer. This designation will provide seven years of market exclusivity, tax credits, and other benefits, enhancing the potential for LP-184's development. LP-184 has shown significant tumor shrinkage in preclinical models, highlighting its promise. The drug targets specific pancreatic cancer patients with certain biomarkers, potentially improving treatment outcomes in a cancer with a poor survival rate of 7.9% over five years.
Lantern Pharma (LTRN) reported its Q2 2021 financial results, highlighting significant advancements in its cancer therapy pipeline. The company aims to expedite drug development using its RADR® A.I. platform, with promising data from its LP-184 program targeting pancreatic cancer and other malignancies. Cash reserves surged to $79.6 million, aided by a $69 million public offering. However, R&D expenses increased to $1.16 million, contributing to a net loss of $2.32 million, or $0.21 per share. Upcoming milestones include clinical trials for LP-300 and data from collaborations with leading cancer research institutions.